Salivary immunity and lower respiratory tract infections in non-elite marathon runners
Por:
Canto, E, Roca, E, Perea, L, Rodrigo-Troyano, A, Suarez-Cuartin, G, Giner, J, Feliu, A, Soria, JM, Nescolarde, L, Vidal, S, Sibila, O
Publicada:
21 nov 2018
Resumen:
Rationale
Respiratory infections are common after strenuous exercise, when salivary immunity may be altered. We aim to investigate changes in salivary immunity after a marathon and its relationship with lower respiratory tract infections (LRTI) in healthy non-elite marathon runners.
Methods
Forty seven healthy marathon runners (28 males and 19 females) who completed the 42.195 km of the 2016 Barcelona marathon were studied. Saliva and blood samples were collected the day before the marathon and two days after the end of the race. Salivary IgA, antimicrobial proteins (lactoferrin, lysozyme) and chemokines (Gro alpha, Gro beta, MCP-1) were determined using ELISA kits in saliva supernatant. Blood biochemistry and haemogram were analyzed in all participants. The presence of LRTI was considered in those runners who reported infectious lower respiratory tract symptoms during a minimum of 3 consecutive days in the 2 weeks after the race.
Results
Eight participants (17%) presented a LRTI during the 2 weeks of follow-up. Higher lysozyme levels were detected after the race in runners with LRTI when compared with those without infection. A decrease in salivary lysozyme, Gro alpha and Gro beta levels after the race were observed in those runners who did not develop a LRTI when compared to basal levels. Salivary Gro alpha levels correlated with basophil blood counts, and salivary lysozyme levels correlated with leukocyte blood counts.
Conclusions
LRTI are common after a marathon race in non-elite healthy runners. Changes in salivary antimicrobial proteins and chemokines are related to the presence of LRTI and correlate with systemic defense cells, which suggest an important role of salivary immunity in the development of LRTI in non-elite marathon runners.
Filiaciones:
Canto, E:
Hosp Santa Creu & Sant Pau, Inst Recerca, Expt Immunol, Barcelona, Spain
Biomed Res Inst St Pau IIB St Pau, Barcelona, Spain
Roca, E:
Univ Politecn Cataluna, Barcelona, Spain
Perea, L:
Hosp Santa Creu & Sant Pau, Inst Recerca, Expt Immunol, Barcelona, Spain
Biomed Res Inst St Pau IIB St Pau, Barcelona, Spain
Rodrigo-Troyano, A:
Biomed Res Inst St Pau IIB St Pau, Barcelona, Spain
Autonomous Univ Barcelona, Hosp Santa Creu & St Pau, Resp Dept, Barcelona, Spain
Suarez-Cuartin, G:
Biomed Res Inst St Pau IIB St Pau, Barcelona, Spain
Autonomous Univ Barcelona, Hosp Santa Creu & St Pau, Resp Dept, Barcelona, Spain
Giner, J:
Biomed Res Inst St Pau IIB St Pau, Barcelona, Spain
Autonomous Univ Barcelona, Hosp Santa Creu & St Pau, Resp Dept, Barcelona, Spain
Feliu, A:
Biomed Res Inst St Pau IIB St Pau, Barcelona, Spain
Autonomous Univ Barcelona, Hosp Santa Creu & St Pau, Resp Dept, Barcelona, Spain
Soria, JM:
Biomed Res Inst St Pau IIB St Pau, Barcelona, Spain
Unit Genom Complex Dis, Barcelona, Spain
Nescolarde, L:
Univ Politecn Cataluna, Barcelona, Spain
Vidal, S:
Hosp Santa Creu & Sant Pau, Inst Recerca, Expt Immunol, Barcelona, Spain
Biomed Res Inst St Pau IIB St Pau, Barcelona, Spain
Sibila, O:
Biomed Res Inst St Pau IIB St Pau, Barcelona, Spain
Autonomous Univ Barcelona, Hosp Santa Creu & St Pau, Resp Dept, Barcelona, Spain
Gold, Green Published
|